Market Overview:
The global herpes zoste drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as the increasing prevalence of herpes zoster, rising demand for better treatment options, and growing awareness about available treatments. Based on type, the global herpes zoste drug market is segmented into acyclovir, amenamevir, FV-100, GLS-5100, GSK-1437173A, NAL-3221 and others. Acyclovir is currently the most popular type of drugs used for treating herpes zoster and it held a major share of the overall market in 2017. However, over time there has been an increase in demand for other types of drugs that are more effective against this virus. This has led to a rise in popularity of newer drugs such as amenamevir and FV-100 which are currently witnessing high adoption rates across various regions. Based on application type ,the global herpes zoste drug market can be segmented into clinic settings , hospital settings and others . Clinic settings accounted for majority share of the overall application segment in 2017 owing to higher adoption rates among patients suffering from this condition . However , with increasing awareness about available treatments options among people , there is an increase in demand for these drugs even outside clinic settings .
Product Definition:
Herpes Zoste Drug is a prescription medication used to treat shingles (herpes zoster), a viral infection that causes a rash. Herpes Zoste Drug is also used to prevent recurrent herpes zoster infections.
Acyclovir:
Acyclovir is a medication used for the treatment of viral infections such as chickenpox, measles, and shingles. It’s most commonly prescribed to people suffering from cold sores or fever blisters. The drug is also used in the treatment of Herpes Zoster (HZ), commonly known as shingles. Acyclovir speeds healing by reducing pain and itching associated with HZ lesions along with decreasing inflammation & swelling caused by them.
Amenamevir:
Amenamevir is a new drug developed to treat patients infected with Herpes Zoster (shingles), which is also used as a preventive measure. It works by decreasing the ability of virus-specific immune cells, known as T cells, to respond to viral infections. Amenamevir was granted fast track and breakthrough therapy approval by the FDA in 2015 and 2016 respectively for shingles and postherpetic neuralgia treatment.
Application Insights:
Based on the application, the global market is segmented into a clinic, hospital and others. The clinic application segment dominated the overall market in 2017 owing to increasing awareness about availability of effective drugs for treatment of diseases such as chickenpox and herpes. Moreover, introduction of new products with fewer side effects is also expected to fuel product demand in this segment over the forecast period.
The hospital application segment was estimated to be one of the largest revenue-generating segments owing to rising prevalence rates of chronic diseases such as HIV/AIDS, tuberculosis and cancer that increase patient admissions in hospitals worldwide. In addition, an increase in number of research studies evaluating these drugs efficacy against various cancers will also boost product demand within this segment over next eight years or so.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of manufacturers and suppliers coupled with high awareness levels among people about zoste drugs are some factors driving the market in this region. In addition, increasing prevalence of target diseases is also expected to drive demand for these drugs over the forecast period. For instance, according to CDC estimates published in 2016, around 6 million people suffer from genital herpes in U.S.
Asia Pacific is expected to be fastest growing region during the forecast period owing to rising healthcare expenditure.
Moreover, introduction.
Growth Factors:
- Increasing incidence of herpes zoster
- Growing awareness about the benefits of herpes zoste drug therapy
- Rising demand for better and more effective therapies for herpes zoster treatment
- Availability of new and innovative drugs for the treatment of herpes zoster
- Growing number of clinical studies on new drugs for the treatment of herpes
Scope Of The Report
Report Attributes
Report Details
Report Title
Herpes Zoste Drug Market Research Report
By Type
Acyclovir, Amenamevir, FV-100, GLS-5100, GSK-1437173A, NAL-3221, Others
By Application
Clinic, Hospital, Others
By Companies
Astellas Pharma Inc., Beijing Minhai Biotechnology Co., Ltd, ContraVir Pharmaceuticals, Inc., Epiphany Biosciences, Inc., Foamix Pharmaceuticals Ltd., GeneOne Life Science, Inc., GlaxoSmithKline Plc, Merck & Co., Inc., NAL Pharmaceuticals Ltd., ReceptoPharm, Inc., TSRL, Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
240
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Herpes Zoste Drug Market Report Segments:
The global Herpes Zoste Drug market is segmented on the basis of:
Types
Acyclovir, Amenamevir, FV-100, GLS-5100, GSK-1437173A, NAL-3221, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Astellas Pharma Inc.
- Beijing Minhai Biotechnology Co., Ltd
- ContraVir Pharmaceuticals, Inc.
- Epiphany Biosciences, Inc.
- Foamix Pharmaceuticals Ltd.
- GeneOne Life Science, Inc.
- GlaxoSmithKline Plc
- Merck & Co., Inc.
- NAL Pharmaceuticals Ltd.
- ReceptoPharm, Inc.
- TSRL, Inc.
Highlights of The Herpes Zoste Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Acyclovir
- Amenamevir
- FV-100
- GLS-5100
- GSK-1437173A
- NAL-3221
- Others
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Herpes Zoste Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Herpes zoster drug is a medication used to treat herpes simplex virus (HSV) infections. It is available as a tablet or injection. Herpes zoster drug works by reducing the number of HSV infections that occur in the body.
Some of the major companies in the herpes zoste drug market are Astellas Pharma Inc., Beijing Minhai Biotechnology Co., Ltd, ContraVir Pharmaceuticals, Inc., Epiphany Biosciences, Inc., Foamix Pharmaceuticals Ltd., GeneOne Life Science, Inc., GlaxoSmithKline Plc, Merck & Co., Inc., NAL Pharmaceuticals Ltd., ReceptoPharm, Inc., TSRL, Inc..
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Herpes Zoste Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Herpes Zoste Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Herpes Zoste Drug Market - Supply Chain
4.5. Global Herpes Zoste Drug Market Forecast
4.5.1. Herpes Zoste Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Herpes Zoste Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Herpes Zoste Drug Market Absolute $ Opportunity
5. Global Herpes Zoste Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Herpes Zoste Drug Market Size and Volume Forecast by Type
5.3.1. Acyclovir
5.3.2. Amenamevir
5.3.3. FV-100
5.3.4. GLS-5100
5.3.5. GSK-1437173A
5.3.6. NAL-3221
5.3.7. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Herpes Zoste Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Herpes Zoste Drug Market Size and Volume Forecast by Application
6.3.1. Clinic
6.3.2. Hospital
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Herpes Zoste Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Herpes Zoste Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Herpes Zoste Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Herpes Zoste Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Herpes Zoste Drug Demand Share Forecast, 2019-2026
9. North America Herpes Zoste Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Herpes Zoste Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Herpes Zoste Drug Market Size and Volume Forecast by Application
9.4.1. Clinic
9.4.2. Hospital
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Herpes Zoste Drug Market Size and Volume Forecast by Type
9.7.1. Acyclovir
9.7.2. Amenamevir
9.7.3. FV-100
9.7.4. GLS-5100
9.7.5. GSK-1437173A
9.7.6. NAL-3221
9.7.7. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Herpes Zoste Drug Demand Share Forecast, 2019-2026
10. Latin America Herpes Zoste Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Herpes Zoste Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Herpes Zoste Drug Market Size and Volume Forecast by Application
10.4.1. Clinic
10.4.2. Hospital
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Herpes Zoste Drug Market Size and Volume Forecast by Type
10.7.1. Acyclovir
10.7.2. Amenamevir
10.7.3. FV-100
10.7.4. GLS-5100
10.7.5. GSK-1437173A
10.7.6. NAL-3221
10.7.7. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Herpes Zoste Drug Demand Share Forecast, 2019-2026
11. Europe Herpes Zoste Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Herpes Zoste Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Herpes Zoste Drug Market Size and Volume Forecast by Application
11.4.1. Clinic
11.4.2. Hospital
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Herpes Zoste Drug Market Size and Volume Forecast by Type
11.7.1. Acyclovir
11.7.2. Amenamevir
11.7.3. FV-100
11.7.4. GLS-5100
11.7.5. GSK-1437173A
11.7.6. NAL-3221
11.7.7. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Mrket Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Herpes Zoste Drug Demand Share, 2019-2026
12. Asia Pacific Herpes Zoste Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Herpes Zoste Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Herpes Zoste Drug Market Size and Volume Forecast by Application
12.4.1. Clinic
12.4.2. Hospital
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Herpes Zoste Drug Market Size and Volume Forecast by Type
12.7.1. Acyclovir
12.7.2. Amenamevir
12.7.3. FV-100
12.7.4. GLS-5100
12.7.5. GSK-1437173A
12.7.6. NAL-3221
12.7.7. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Herpes Zoste Drug Demand Share, 2019-2026
13. Middle East & Africa Herpes Zoste Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Herpes Zoste Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Herpes Zoste Drug Market Size and Volume Forecast by Application
13.4.1. Clinic
13.4.2. Hospital
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Herpes Zoste Drug Market Size and Volume Forecast by Type
13.7.1. Acyclovir
13.7.2. Amenamevir
13.7.3. FV-100
13.7.4. GLS-5100
13.7.5. GSK-1437173A
13.7.6. NAL-3221
13.7.7. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Herpes Zoste Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Herpes Zoste Drug Market: Market Share Analysis
14.2. Herpes Zoste Drug Distributors and Customers
14.3. Herpes Zoste Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Astellas Pharma Inc.
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Beijing Minhai Biotechnology Co., Ltd
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. ContraVir Pharmaceuticals, Inc.
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Epiphany Biosciences, Inc.
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Foamix Pharmaceuticals Ltd.
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. GeneOne Life Science, Inc.
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. GlaxoSmithKline Plc
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Merck & Co., Inc.
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. NAL Pharmaceuticals Ltd.
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. ReceptoPharm, Inc.
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. TSRL, Inc.
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
